Medical News

RSS

Adenovirus used to destroy cancer cells

With nearly $1 million in government funding, University of Rochester scientists are testing a new innovation in biotherapy by altering a common childhood respiratory virus, the adenovirus, to destroy cancer cells.

23 Jun 2007

RNA polymerase points to new targets for drug design

Researchers at UAB (University of Alabama at Birmingham) have new information on the structure of a key enzyme in bacteria that could lead to improved antibiotics and less antibiotic resistance.

23 Jun 2007

Goltz syndrome gene found

Researchers funded in part by the National Institutes of Health have identified the gene that accounts for most cases of Goltz syndrome, a rare skin disorder that can also affect bone and eye development.

23 Jun 2007

Research links childhood social skills and learning abilities

While federal programs such as No Child Left Behind emphasize the importance of academic skills to school success and achievement, there is growing interest in how social skills develop and how they contribute to learning.

23 Jun 2007

Ranbaxy receives tentative approval to manufacture Amlodipine Besylate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base).

23 Jun 2007

Truth on postmenopausal hormone therapy and coronary disease

With each new publication of coronary artery disease (CAD) data from the Women's Health Initiative (WHI) study, the inevitable reaction is ,Why on earth did the WHI investigators claim in 2002-2004 that postmenopausal hormone therapy has deleterious effects on the risk for CAD, when, from the beginning, they were aware of the importance of the age factor in this clinical scenario".

23 Jun 2007

40 percent of parents willing to have their child's DNA stored in a government biobank

Genetic testing holds great promise for the future. Information generated by genetic testing may provide information that leads to new treatments for common diseases such as heart disease and diabetes.

23 Jun 2007

Mid-life stroke in women

More women than men appear to be having a stroke in middle age, according to a study published June 20, 2007, in the online edition of Neurology, the medical journal of the American Academy of Neurology.

23 Jun 2007

Many couples willing to donate unused embryos to stem cell research

In a survey of over a thousand patients who have created and frozen embryos as part of fertility treatment, 60 percent said they would be likely to donate unused embryos for stem cell research, according to a study led by researchers at Duke University Medical Center and Johns Hopkins University.

23 Jun 2007

Kidney specialists review plans for disaster response

Hurricane Katrina and other recent disasters have focused attention on the urgent need for planning to provide health services after natural disasters.

23 Jun 2007

First genome-scale model of microbe that causes tuberculosis

Tuberculosis remains one of the biggest killers in the world today being responsible for nearly ten million cases and one and a half million deaths each year.

23 Jun 2007

Key mechanism identified by which the body regulates iron metabolism

Scientists at the University of California, San Diego (UCSD) have determined a key mechanism by which the body regulates iron metabolism, a discovery that may provide new approaches for the treatment of anemia.

23 Jun 2007

Entecavir can compromise HIV treatment

Treating hepatitis B patients with the drug entecavir can cause those who are also infected with HIV to become resistant to two of the most important drugs in the anti-HIV arsenal, according to a new report in the New England Journal of Medicine.

23 Jun 2007

FDA approves Differin (adapalene) gel, 0.3% for acne

Galderma Laboratories, L.P., has announced that the U.S. Food and Drug Administration (FDA) has approved Differin (adapalene) Gel, 0.3%, a new, higher concentration formulation of Differin (adapalene) 0.1%, a topical retinoid indicated for the treatment of acne.

23 Jun 2007

Genzyme files for FDA approval of single-treatment Synvisc-One

Genzyme Corp. has announced that it has filed with the U.S. Food and Drug Administration (FDA) for approval of Synvisc-One, the single treatment of Synvisc (hylan G-F 20) that provides up to six months of pain relief from osteoarthritis (OA) of the knee.

23 Jun 2007